BACKGROUND: Synergistic neuromuscular blocking effects have been observed clinically with certain pairs of nicotinic acetylcholine receptor (nAChR) competitive antagonists. The mechanism for synergy has not been elucidated. We tested the hypothesis that synergy arises from a differential selectivity of antagonists for the two ligand binding sites on adult human nAChR. METHODS: We expressed nAChR in BOSC23 cells. We applied ACh with or without antagonists to outside-out patches and measured macroscopic currents at room temperature. We determined the IC 90 for (ϩ)-tubocurarine, metocurine, pancuronium, vecuronium, cisatracurium, rocuronium, and atracurium. For 15 combinations of two antagonists, we determined the IC 90 for one antagonist in the presence of the IC 70 of a second antagonist. We constructed isobolograms for 90% inhibition. For single antagonists, we measured inhibition of receptors containing mutations in the ⑀and ␦-subunits to determine site selectivity. RESULTS: Two pairs of antagonists, metocurineϩcisatracurium and cisatracuriumϩ atracurium exhibited additive inhibition. Ten combinations, including (ϩ)-tubocurarineϩ pancuronium and pancuroniumϩvecuronium, were highly synergistic such that the combination was two to three times more effective than expected for additivity. Three combinations were 1.5-1.6 times more effective than expected for additivity. Inhibition by (ϩ)-tubocurarine and metocurine was sensitive to mutations in the ⑀-subunit only. Vecuronium was affected by the ␦-subunit mutation only. Inhibition by other antagonists was decreased by mutations in either subunit. CONCLUSIONS: Many combinations of antagonists exhibited synergistic effects on adult human nAChR. Synergy was observed with structurally similar and dissimilar antagonists. The degree of synergy did not always correlate well with site specificity assayed with mutants. In some, but not all cases, the synergy at the receptor level correlated with clinical determinations of synergy. We conclude that the synergistic actions of muscle relaxants can be partially explained by direct interactions with adult human nAChR.
BACKGROUND: Synergistic neuromuscular blocking effects have been observed clinically with certain pairs of nicotinic acetylcholine receptor (nAChR) competitive antagonists. The mechanism for synergy has not been elucidated. We tested the hypothesis that synergy arises from a differential selectivity of antagonists for the two ligand binding sites on adult human nAChR. METHODS: We expressed nAChR in BOSC23 cells. We applied ACh with or without antagonists to outside-out patches and measured macroscopic currents at room temperature. We determined the IC 90 for (ϩ)-tubocurarine, metocurine, pancuronium, vecuronium, cisatracurium, rocuronium, and atracurium. For 15 combinations of two antagonists, we determined the IC 90 for one antagonist in the presence of the IC 70 of a second antagonist. We constructed isobolograms for 90% inhibition. For single antagonists, we measured inhibition of receptors containing mutations in the ⑀and ␦-subunits to determine site selectivity. RESULTS: Two pairs of antagonists, metocurineϩcisatracurium and cisatracuriumϩ atracurium exhibited additive inhibition. Ten combinations, including (ϩ)-tubocurarineϩ pancuronium and pancuroniumϩvecuronium, were highly synergistic such that the combination was two to three times more effective than expected for additivity. Three combinations were 1.5-1.6 times more effective than expected for additivity. Inhibition by (ϩ)-tubocurarine and metocurine was sensitive to mutations in the ⑀-subunit only. Vecuronium was affected by the ␦-subunit mutation only. Inhibition by other antagonists was decreased by mutations in either subunit. CONCLUSIONS: Many combinations of antagonists exhibited synergistic effects on adult human nAChR. Synergy was observed with structurally similar and dissimilar antagonists. The degree of synergy did not always correlate well with site specificity assayed with mutants. In some, but not all cases, the synergy at the receptor level correlated with clinical determinations of synergy. We conclude that the synergistic actions of muscle relaxants can be partially explained by direct interactions with adult human nAChR. Thecl inical use of nondepolarizing muscle relaxants to produce paralysis during surgery began in 1942 with (ϩ)-tubocurarine, a benzylisoquinoline extracted from a South American vine. 1 In 1964, pancuronium, a derivative of a steroid toxin found in an African plant, was introduced. The common structural feature of these drugs, one [(ϩ)-tubocurarine] or two (pancuronium) quaternary ammonium groups, confers high affinity binding to the muscle nicotinic acetylcholine receptor (nAChR). The drugs are competitive antagonists of the nAChR.
In the 1980s, certain combinations of nondepolarizing competitive muscle relaxants were observed to have super-additive, or synergistic, neuromuscular blocking effects. [2] [3] [4] [5] The classic example is the combination of (ϩ)-tubocurarine and pancuronium. A 95% depression of a single twitch (ED 95 ) required either 0.51 mg/kg of (ϩ)-tubocurarine or 0.07 mg/kg of pancuronium. 2 However, when the two drugs were combined, ED 95 was achieved with Ͻ1/3 the dose of each drug. 2 Synergy has been observed for other combinations often, but not exclusively, with one benzylisoquinoline and one aminosteroid. Combinations of muscle relaxants have been also examined in animal studies of neuromuscular junction 6 -8 and isolated muscle preparations. 9 With one exception, 8 synergy was observed with (ϩ)-tubocurarine or metocurine and pancuronium.
The nAChR has two, non-identical binding sites for acetylcholine (ACh) located at the interface between the ␣and ␦-subunits and the interface between the ␣and ⑀-subunits ( Fig. 1) . ACh itself has a sixfold preference for the ␣-⑀ interface at the adult human nAChR. 10 (ϩ)-tubocurarine and metocurine also favor the ␣-⑀ interface but by factors of 15 and 80 respectively. 11 In embryonic nAChR in which the ⑀-subunit is replaced by a ␥-subunit, (ϩ)-tubocurarine and metocurine favor the ␣-␥ interface. Interestingly, distinct amino acid residues confer high selectivity to the ⑀ and ␥-subunits. 12,13 A 26-fold site selectivity has been seen for pancuronium in adult mouse nAChR 14 and there is evidence that the ␣-␦ interface has the higher affinity. 15 The hypothesis that synergy arises from selective binding of (ϩ)-tubocurarine and pancuronium to opposite interfaces ( Fig. 1 ), originally proposed by Waud and Waud in 1985, 9 was tested in vitro by Paul et al. 16 They expressed the subunits of adult mouse nAChR in oocytes and measured the inhibition of ACh-induced currents by pairs of muscle relaxants. They found no evidence for synergy and concluded that synergy must arise from some other process, perhaps involving presynaptic nAChRs. These experiments, however, were performed under conditions of relatively low receptor occupancy. When receptor occupancy is low, it can be difficult to distinguish between competition and synergy. 9, 17 There is another reason to use conditions of high receptor occupancy when looking for in vitro evidence of synergy. Nature has provided fast-twitch skeletal muscle with a high margin of safety. 18 The origin of the safety margin is a combination of a bountiful release of neurotransmitter from the presynaptic nerve terminal, a copious density of receptors on the postsynaptic membrane and a generous supply of action-potential-triggering sodium channels at the muscle endplate. 19, 20 In cat tibialis and sartorium muscles, a receptor occupancy of 0.76 Ϯ 0.05 is needed before any diminution of muscle contraction is detected and the receptor occupancy required for complete block is 0.917 Ϯ 0.16. 18 The margin of safety for the diaphragm muscle may be even higher. 21 Although it is sometimes argued that the margin of safety is lower in human muscle compared with other mammals, neuromuscular transmission in normal humans rarely fails. 20, 22 Here, we use patch clamp recording to test for in vitro evidence of synergy between pairs of muscle relaxants on adult human nAChR. Specifically, we consider high levels of receptor occupancy to determine the IC 90 of individual drugs and drug combinations. These conditions should be comparable to in vivo determinations of CE 50 values for muscle relaxation.
METHODS
Human adult muscle nAChRs were expressed in BOSC23 cells, a subclone of human embryonic kidney 293 (HEK-293) cells (American Type Culture Collection, Manassas, VA), using a lipid-based reagent (Fu-GENE 6, Roche Diagnostics, Basel, Switzerland). Cells were transfected with cDNA coding for subunits of human nAChR 23 : ␣, ␤, ⑀, and ␦ (gift of Dr. Steven Sine). cDNA for CD8 (gift of Dr. Brian Seed), a T-cell antigen used as a marker 24 was co-transfected. The AChR cDNA was cloned into the pRBG4 expression vector; the CD8 cDNA was cloned into the H3-CD8 expression plasmid. The mutations ⑀D59A, ⑀D173A, and ␦D180K were prepared from wild-type ⑀or ␦-subunit by bridging with a 20-base pair oligonucleotide. DNA sequencing confirmed the constructs. Experiments were performed on cells in 2-3 days after transfection. Cells were prepared for patch-clamp recording as described before. 25, 26 An extracellular solution (ECS) contains 150 mM NaCl, 5.6 mM KCl, 1.8 mM CaCl 2 , 1.0 mM MgCl 2 , and 10 mM HEPES, pH 7.3. In order to identify transfected cells, 2-3 L of polystyrene beads coated with a monoclonal antibody specific for the CD8 antigen (Dynabeads; Invitrogen Corporation, Carlsbad, CA) were added in the cell dish. Cells with two or more beads attached were considered likely to express nAChR and CD8. 24 NaCl, KCl, and CaCl 2 were obtained from Mallinckrodt Baker, Inc. (Phillipsburg, NJ); MgCl 2 was obtained from Fisher Scientific (Fairlawn, NJ); HEPES, EGTA, acetylcholine chloride (purity Ͼ99%), (ϩ)tubocurarine chloride (purity 98%), pancuronium dibromide (purity Ͼ99%) and atracurium besylate were Figure 1 . The hypothesis for the origin of synergy between (ϩ)-tubocurarine and pancuronium. There are two distinct binding sites for acetylcholine (ACh) and competitive antagonists of the muscle nicotinic ACh receptor. ACh must bind to both sites before the channel can open efficiently. (ϩ)-tubocurarine has a higher affinity for the binding site at the ␣⑀ interface than at the ␣␦ interface. The hypothesis is that pancuronium has a higher affinity for the binding site at the ␣␦ interface. In this case, the two antagonists would bind nearly independently and inhibition would be synergistic. obtained from Sigma-Aldrich Corp. (St. Louis, MO). Metocurine iodide was synthesized 27 from (ϩ)tubocurarine at the Chemical Synthesis Center, Department of Chemistry, Stony Brook University. Purity of 99% was determined by 1 H-NMR. Vecuronium bromide was obtained as the clinical formulation Norcuron ® from Bedford Labs (Bedford, OH), 1 mg/mL (1.8 mM) in a solution containing 2.1 mg/mL anhydrous citric acid, 1.6 mg/mL sodium phosphate and 9.7 mg/mL mannitol. Dilutions were prepared in distilled water. The highest concentration of vecuronium used, 1 M, contained 95 M mannitol. Rocuronium bromide was obtained as the clinical formulation Zemuron ® from Baxter Pharmaceutical Solutions LLC (Deerfield, IL), 1 mg/mL (16.4 mM). Cisatracurium besylate was obtained as the clinical formulation Nimbex ® from GlaxoSmithKline (Philadelphia, PA), 2 mg/mL (2.1 mM) in a 35% benzene sulfonic acid solution. Dilutions were prepared in distilled water. The highest concentration of cisatracurium used, 1 M, contained 0.017% benzene sulfonic acid.
Patch pipettes filled with a solution consisting of 140 mM KCl, 5 mM EGTA, 5 mM MgCl 2 , and 10 mM HEPES, pH 7.3, had resistances of 2 to 7 M⍀. An outside-out patch 28 with a seal resistance of Ն2 G⍀ was excised from a cell and moved into position at the outflow of a HSSE-2 rapid perfusion system (ALA Scientific Instruments, Westbury, NY). The gravitycontrolled perfusion system consists of solution reservoirs, manual switching valves, a solenoid-driven pinch valve, and two Teflon tubes inserted into the culture dish. 29 One tube contained ECS or (ECSϩantagonist); the other contained (ECSϩACh) or (ECSϩAChϩantagonist). A saturating concentration of 300 M ACh was used to activate currents in wild-type, ⑀D59A and ⑀D173A nAChR. Activation of ␦D180K nAChR required 1.5 mM ACh for maximal currents. Manual valves were used to connect to reservoirs containing a defined concentration of competitive antagonist with or without ACh. The system allows a rapid (0.1-1 ms) exchange of the solution bathing the excised patch. 29 The patch was clamped at Ϫ50 mV while a series of 10 -20, 250 ms applications of ACh-containing solution was applied at a 5-s interval. Currents were digitized at 100 s per point and high-pass filtered at 3 kHz with a patch clamp amplifier (EPC-9, Heka Instruments, Inc., Port Washington, NY).
In experiments with a single antagonist, control currents and recovery currents were obtained with antagonist-free solutions, test currents were obtained with antagonist-containing solutions. In experiments with pairs of antagonists, the control and recovery currents were obtained in the presence of 2 ϫ IC 50 of antagonist 1 and test currents were obtained in the presence of 2 ϫ IC 50 of antagonist 1 ϩ different concentration of antagonist 2 . An experiment was accepted if the recovery currents were at least 80% of the control currents. At least six concentration points were used for every antagonist; at least one of these produced Ͼ90% inhibition. Relative currents were calculated as the ratio of the test current, I 1 , to the average of the control and recovery currents, I 0 . The Hill Equation was used to determine the IC 50 , the concentration needed to produce a 50% inhibition of the current and the Hill coefficient, n H .
The IC 90 of an antagonist was determined by setting I 1 /I 0 ϭ 0.1.
Predicted isobolograms were calculated assuming a two site, two drug binding model. 18
where R is the relative number of unliganded receptors, L ␣⑀1 , L ␣␦1 , L ␣⑀2 , and L ␣␦2 are the equilibrium dissociation constants at the ␣-⑀ interface (L ␣⑀ ) or the ␣-␦ interface (L ␣ ␦) for antagonist 1 or antagonist 2 . The isobologram for 90% inhibition is calculated by setting R ϭ 0.1. Fractional analysis 30, 31 was used to quantify the degree of synergy with pairs of antagonists. The individual concentrations of the two antagonists in a combination were calculated as fractions of the concentrations that produce the same 90% inhibition of the macroscopic currents when the antagonists were given separately. 
Statistics
Curve fitting of data to Equation 1 was performed using Igor Pro 6.02 (WaveMetrics, Inc., Oswego, OR). IC 50 , n H , IC 90 and data points in figures are given with average values Ϯ standard deviations from 4 to 9 separate patches. The fractional analyses are presented as averages with 95% confidence intervals. In experiments with mutant nAChR, inhibition was measured at the antagonist concentration needed to produce a relative current of 0.33 in wild-type receptors. A one-sample, two-sided, t-test was used to determine whether the observed relative current was different from 0.33 using Stata 9.2 (StataCorp, College Station, TX). Difference were considered to be statistically significant if P Ͻ 0.05. Figure 2a shows representative traces from an experiment with 50 nM (ϩ)-tubocurarine. Threehundred M ACh activates Ͼ95% of the approximately 300 AChR channels in the patch within 1 ms. The peak current is followed by a decay due to desensitization; time constant ϭ 174 ms in this example. In the presence of 50 nM (ϩ)-tubocurarine, the peak current is decreased by about 60%. Peak currents are plotted as a function of antagonist concentration and fitted to the Hill equation (Fig. 2B ). For (ϩ)tubocurarine, IC 50 ϭ 24 Ϯ 2 nM and the Hill coefficient is close to 1.0. The IC 90 is approximately 10-times the IC 50 , 286 Ϯ 70 nM for (ϩ)-tubocurarine. Results for all the antagonists in this study are presented in Table 1 . For comparison, we include estimates of the clinical concentrations of the antagonists that decrease muscle tension by 50%, CE 50 , based on pharmacokinetic/ pharmacodynamic modeling. 32, 33 Inhibition of nAChRs by Pairs of Antagonists Figure 3 illustrates the steps used to construct a nAChR isobologram for two antagonists. Figures 3A  and B show the concentration-response curves for (ϩ)-tubocurarine and pancuronium respectively. We determined the IC 90 values and used them as the end-points for the line of additivity in the isobologram in Figure 3D . We then measured a concentrationresponse curve for (ϩ)-tubocurarine in the presence of 15 nM pancuronium, the concentration equal to 2 ϫ IC 50 of pancuronium (Fig. 3C) . Thus, the low (ϩ)tubocurarine concentration asymptote for the curve in Figure 3C is 0.33. The IC 90 for (ϩ)-tubocurarine in the presence of 15 nM pancuronium is 63 nM. The point (15 nM, 63 nM) is plotted on the isobologram (Fig. 3D ). As can be seen from Figure 3D , the combination of (ϩ)-tubocurarine and pancuronium are highly synergistic for blocking 90% of AChR currents. The fractional IC 90 doses are 0.22 and 0.16 for (ϩ)-tubocurarine and pancuronium respectively, giving a total fraction dose of 0.38 (0.25, 0.53) (95% CI). For comparison, the fractional dose for these antagonists on patients is 0.63. 2 An alternate way to present data from two antagonists is to consider the apparent IC 50 of antagonist 2 in the presence of antagonist 1 . In Figure 4A , we normalized the concentration-response curve of (ϩ)-tubocurarine ϩ 15 nM pancuronium to that of (ϩ)-tubocurarine alone. The IC 50 values of the two curves are essentially the same, 25 nM. This suggests that the two antagonists bind to the AChR independently rather than compete for the same site. In contrast, Figure 4B shows a similar comparison for metocurine and cisatracurium. The IC 50 of metocurine alone is 18 nM. The apparent IC 50 of metocurine in the presence of 20 nM cisatracurium is shifted to 59 nM. This shift to a lower potency is consistent with competition. (32, 33) . They are not corrected for the free fraction of drug after accounting for protein binding which ranges from 0.31 for vecuronium to 0.63 for atracurium (33) .
RESULTS

Inhibition of AChRs by Individual Antagonists
For three pairs of antagonists, we experimentally determined additional points on the isobolograms (Fig. 5) . We varied the parameters in Equation 2 to obtain an isobologram with R ϭ 0.1 using Equation 2 (dashed line) that intersected the initial experimental point (solid square). We then chose several additional concentration pairs that lie on the isobologram (open squares). The inhibition produced by these additional concentration pairs was determined on four to six patches. In all cases, the ratios of resulting currents compared to antagonist-free controls were not significantly different from 0.1 (Fig. 5 insets) . Figure 5A shows the results for vecuroniumϩpancuronium. They exhibited strong synergy over the entire isobologram. The combination of (ϩ)-tubocurarineϩcisatracurium ( Fig. 5B ) exhibited weaker but significant synergy. The combination of metocurineϩcisatracurium was additive (Fig. 5C) .
The results for all pairs of antagonists are summarized in Table 2 . The total fractional doses are significantly Ͻ1.0 (the 95% confidence limits do not overlap 1.0) for all combinations except metocurineϩcisatracurium and atracuriumϩcisatracurium. Clinical values for fractional doses are included for those combinations that have been reported.
Inhibition of Mutant Receptors
To test the hypothesis that synergy arises from differential binding of antagonists to the two binding interfaces, we made mutations in the ⑀-subunit that without cisatracurium. The data for pairs of antagonists are scaled to match the maximum value in the single antagonist curve (note right-hand axes). There is no shift in the apparent IC 50 of (ϩ)-tubocurarine when 15 nM pancuronium is present; this suggests that the antagonists bind independently. There is a three-fold shift in the apparent IC 50 of cisatracurium when 40 nM metocurine is present; this suggests that the antagonists compete for the same binding sites.
Vol. 107, No. 2, August 2008 have been previously identified to alter the binding affinity for metocurine and/or (ϩ)-tubocurarine. 11 We also examined a mutation, ␦D180K, which decreases binding of both ACh and (ϩ)-tubocurarine to the ␦-subunit in mouse nAChR. 34 We found that it also decreased the sensitivity of adult human nAChR to ACh. The current response saturated with application of 1.5 mM ACh without causing appreciable open channel block at Ϫ50 mV (not shown). Thus, experiments with ␣ 2 ␤⑀␦(D180K) were performed with 1.5 mM ACh instead of the 0.3 mM used in all other experiments.
If a mutation in a subunit changes the affinity for a drug, this suggests that the drug has significant interactions with that subunit interface. If there is no change in affinity, the result is inconclusive. Figure 6 summarizes the results. In all cases, the mutations either reduced the affinity of the receptor for the drugs (less inhibition at a fixed concentration) or caused no Figs. 3 and 4) . The solid lines isobolograms that fit the closed symbol data point. Open symbols indicate concentration pairs that lie on the isobologram and should produce a relative current (Rel Curr) of 0.1. The insets show the measured relative current produced by these additional concentration pairs. None of the additional pairs produced a relative current significantly different from 0.1. change. As expected from previously published data, (ϩ)-tubocurarine and metocurine are sensitive to mutations in the ⑀-subunit but not in the ␦-subunit. Vecuronium is insensitive to the two ⑀-subunit mutations but is sensitive to the ␦-subunit mutation. Inhibition by the other antagonists is sensitive to mutations in either subunit.
DISCUSSION
Synergism between pairs of muscle relaxant drugs has been observed in vivo with human adductor pollicis muscle using either single twitch or train-offour ratio to assay muscle function. [2] [3] [4] [5] [35] [36] [37] It has also been investigated in animals: rat phrenic nervehemidiaphragm, 6 guinea pig nerve-lumbrical muscle, 7 isolated guinea pig lumbrical muscle 9 and rat sciatic nerve-tibialis muscle. 8 The fact that synergy was reported in most of these preparations (with the exception of reference 8 ) suggests that pharmacokinetic effects are not important. (However, pharmacokinetics may play a role in the interaction between mivacurium and pancuronium due to hydrolysis of mivacurium by butyrylcholinesterase 38 ). Synergy was investigated at the receptor level using adult mouse nAChR expressed in oocytes. 16 These investigators found no evidence for synergy in their study.
Most of the clinical results are consistent with each other. Additive block was mainly observed with antagonists of similar structures, whereas super-additive block was observed with different structural classes of antagonists (reviewed in 39 ). Combinations of benzylisoquinoliniums, such as (ϩ)-tubocurarineϩmetocurine and cisatracuriumϩatracurium are additive. 2, 35 The combination of two aminosteroids, pancuronium, and vecuronium, are also additive. 3 Synergy was seen for pairs of antagonists with different structures, e.g., metocurine and pancuronium, 2 (ϩ)-tubocurarine and pancuronium 2 and cisatracurium and vecuronium or rocuronium. 35 We studied human adult muscle nAChRs expressed in BOSC23 cells and found evidence for synergy between many pairs of both similar and dissimilar antagonists. This differs from a previous study of expressed receptors in which no combinations of antagonists exhibited synergy. 16 The methods used in the two studies differ in several respects. We used human instead of mouse AChR, we used outside-out patches from a mammalian expression cell line instead of frog oocytes and we examined IC 90 levels of antagonist concentrations instead of IC 50 levels. All of these factors probably contribute to the different conclusions of the studies. First, the other investigators examined whether the combination of the IC 25 of drug A plus the IC 25 of drug B was equipotent to the IC 50 of a single drug. If the drugs acted competitively, this combination would produce a current 0.50 times the antagonist-free control. If the drugs acted independently, IC 25A ϩ IC 25B would produce a current 0.44 times the antagonist-free control (Equation 2). These predictions differ by 12%. In contrast, a comparison of the IC 45 of the drug combination with the IC 90 of a single drug, yields predictions of 0.033 versus 0.099. This threefold difference in predictions is considerably easier to detect. Figure 7 presents isobolograms derived from Equation 2 for different levels of receptor occupancy. Others have also discussed this concept. 9, 17 Second, we have noted differences in the effects of antagonists between human and mouse AChR. For example, we found that combinations of pancuronium or vecuronium with (ϩ)-tubocurarine were not synergistic on mouse AhCR (unpublished results). Third, the use of outsideout patches provides ms time resolution to better determine the action of drugs that associate and dissociate on this time scale. 25, 26 Most importantly, muscle relaxation occurs only when there is a high occupancy of receptors by antagonists. 20 A drawback to using such high levels of inhibition in electrophysiology experiments is that the receptor concentrationresponse curve is relatively flat in this range and this leads to large uncertainties in IC 90 values. In contrast, these concentrations are within the steep part of the in vivo curves because of the high margin of safety.
We examined nine combinations of antagonists that can be compared to published clinical data ( Table 2 ). Of these, five show qualitative agreement in that the fractional analysis values are significantly Ͻ1.0 [(ϩ)-tubocurarine/pancuronium, (ϩ)tubocurarine/vecuronium, vecuronium/cisatracurium, cisatracurium/rocuronium] or essentially equal to 1.0 (atracurium/cisatracurium). Thus, for these five, dissimilar antagonists are synergistic and similar drugs are additive. The remaining four combinations involve structurally similar drugs that are additive in human studies but synergistic in our experiments. One possible explanation is that there are important differences in nAChR behavior between our in vitro preparation and in vivo conditions. Certainly, an outside-out patch of non-muscle membrane containing heterologously expressed receptors provides only a minimalist approximation of the physiological environment of nAChR at the neuromuscular junction. However, the data in Table 1 indicate that there is a very good correlation between the in vivo CE 50 and in vitro IC 90 values for antagonists. (The IC 50 values determined by us are similar to those reported by Jonsson et al. 40 for adult human nAChR expressed in oocytes.) One difference between the two conditions is temperature. We have found that increasing temperature from 25°C to 37°C decreases the affinity of embryonic mouse muscle nAChR for antagonists by a factor of 1.7 to 1.9, but increases the association and dissociation rates by two to fivefold and this is antagonist-dependent. 41 The effect of temperature on synergy is unknown. Alternatively, the muscle nAChR may not be the only molecular actor that participates in muscle relaxant synergy. In addition, there are neuronal nAChRs 42 and purinergic receptors 43, 44 that may modulate activity at the neuromuscular junction.
A commonly invoked explanation for muscle relaxant synergy involves the role of presynaptic neuronal nAChRs. 16 These receptors are thought to provide a positive feedback mechanism for vesicular ACh release by prolonging nerve terminal depolarization and increasing intracellular calcium. 42 (However, there is also evidence for a presynaptic negative feedback mechanism 45 ). In this explanation, synergy results if one antagonist acts primarily on the postsynaptic nAChR and the other acts on the presynaptic nAChR. There are several lines of evidence that argue against such a scenario. (a) The correlation between clinical and experimental concentrations of antagonists (Table  1) suggests that all of the muscle relaxants produce a similar inhibition of muscle nAChRs at clinical concentrations. (b) Muscle relaxants are much less potent on human neuronal nAChR subtypes (including ␣3␤2, the subtype found on mouse motor neurons 46 ) than they are on human muscle nAChR. 40 Based on these data, the calculated inhibition of ␣3␤2 nAChR at in vivo CE 50 concentrations is 3% (pancuronium), 5% (cisatracurium), 7% (vecuronium), 12% [(ϩ)-tubocurarine] and 22% (rocuronium). Because the inhibition of muscle nAChR is already Ն90% at CE 50 concentrations (Table  1) , it is not clear how inhibition of presynaptic receptors could make a substantial contribution. (c) Inhibition of the presynaptic feedback mechanism might possibly produce the phenomenon of fade during repetitive stimuli, 42 but it is unlikely to affect the twitch response to a single stimulus.
Experiments with nAChR mutants must be interpreted carefully. The lack of an effect by a mutation does not eliminate that site or subunit as a possible antagonist binding site. The presence of an effect by a mutation is good, but not conclusive, evidence that the site is important for binding. There is always the possibility of large-scale structural rearrangement of the protein due the mutation. In our experiments, all of the functional mutations decreased inhibition by antagonists; thus, the mutations did not create new binding sites, but decreased affinity for existing sites. However, the data obtained with mutant receptors (Fig. 6 ) do not completely clarify the molecular origins of antagonist synergy. For example, we found the combination of (ϩ)-tubocurarine and pancuronium to be highly synergistic. The isobologram in Figure 3D assumes that the two antagonists are highly selective (Ն100:1) for opposite binding sites. The mutation data suggest, though, that pancuronium has a significant affinity for both sites. Similarly, vecuronium and pancuronium show a high degree of synergy ( Fig. 5A ) and yet both are affected by a mutation on the ␦-subunit. And, most surprisingly, (ϩ)-tubocurarine and metocurine, which both have high affinity for the ␣-⑀ interface, show synergistic effects in our experiments. One possible explanation is that antagonist binding to one site is accompanied by a conformational change in the nAChR that affects the affinity of the other site. There is evidence to suggest that this may be the case. 26, 41 In summary, we found that several combinations of competitive antagonists for human adult muscle AChR show evidence for synergy when tested at high receptor occupancy. The negative results reported in a previous attempt to measure synergy in vitro 16 may have arisen from the use of lower concentrations of antagonists. Our findings, however, could not be interpreted in terms of a scheme in which antagonists had preferential binding for one of the two ligand binding sites on the nAChR (Fig. 1 ). We suggest that conformational changes induced by antagonist binding may contribute to synergistic effects. Some of our findings correlate with clinical measures of synergy in humans, but others do not. We suggest that temperature differences may be important. Alternatively, proteins found at the neuromuscular junction, but not included in our outside-out patches, may play a role.
